

Accelerating Innovation in Dementia through Public Private Partnerships:

*The Innovative Medicines Initiative (IMI) and its
neurodegeneration portfolio*

Elisabetta Vaudano • IMI Principal Scientific Manager
Alzheimer's Europe Conference The Hague - NL- October 24th 2019


IMI – Europe's partnership for health

IMI1: 2008-2013

€2 bn budget
59 projects

IMI2: 2014-2020

€3.3 bn budget
More ambitious
More open
Greater scope




IMI – Europe's partnership for health

IMI mission

IMI facilitates open collaboration in research to advance the development of, and accelerate patient access to, personalised medicines for the health and wellbeing of all, especially in areas of unmet medical need.

IMI2 JU **SRA** (https://www.imi.europa.eu/sites/default/files/uploads/documents/About-IMI/research-agenda/IMI2_SRA_March2014.pdf) is fully aligned with both the EU's health research priorities, and the World Health Organisation's Priority Medicines for Europe and the World report.

IMI 2 budget (2014 – 2020)



EFPIA Partners in Research



IMI2 Associated Partners as of March 2019

Accelerate Diagnostics
Autism Speaks
Autistica
BD Switzerland Sarl
Bill and Melinda Gates Foundation (BMGF)
Bio-rad Laboratories
Cepheid Europe
CHDI Foundation
Children's Tumour Foundation
Diamond Light Source
International Diabetes Foundation
Invicro
JDRF
KTH Royal Institute of Technology

Leona M. and Harry B. Helmsley
Charitable Trust
McGill University
Medicines for Malaria Venture
Obesity Action Coalition
Ontario Institute of Cancer Research
Parkinson's UK
Simon Foundation Autism Research
Initiative (SFARI)
Software AG
Springworks Therapeutics
T1D Exchange (formerly Unitio)
TB Alliance
University of Dundee
Wellcome Trust

Total Number of Associated Partners:	27
Total EUR committed:	EUR 162,232,214

What do we attack in IMI?

- IMI is not for everyone and it is not for everything
- But we can tackle some big things that other mechanisms cannot

Some examples:

- Pooling of assets from disparate sources (across the public/private divide) in order to do impactful things
- Complex technology platforms that require scale for success
- Catalysing new infrastructures representing significant gaps in the system
- Tackling really big societal challenges that seem to be “stuck”
- Problems where different stakeholder groups are required to be at the same table from day 1
- Opportunities for technology convergence to be operationalised in high risk areas
 - New actors- new industrial sectors- important role for European SMEs*
- Areas that challenge the traditional thinking around the precompetitive space

IMI: we make connections and break silos




Picture Credit: Public Works Knowledge Network


IMI – Ecosystem for innovative collaborations

IMI is a **neutral platform** where **all involved** in drug development can engage in **open collaboration** on **shared challenges in areas of unmet medical needs**.

All partners needed to find transformative solutions to **reduce late stage attrition, speed patient access** and **improve health outcomes** and find solutions for a sustainable healthcare system



Patient involvement in IMI projects




Moving forward: from initial to strategic patient engagement

The IMI
Scientific
Committee
includes a
patient
representative


IMI pool of patient experts who will:

- Contribute to shaping the IMI portfolio and improve quality of IMI projects from patient perspective through early & meaningful engagement.
- Support and enhance patient involvement in IMI projects.
- Support identification of patient-relevant results and, where appropriate, their implementation in research, regulatory and medical practice.

118 patients and 39 family members / informal carers including **three people with dementia and three supporters from the European Working Group of People with Dementia**



The dementia tsunami




Source: [World Alzheimer Report 2018 by Alzheimer's Disease International](#)

Dementia and Alzheimer's Disease

Dementia

- *A set of symptoms*
 - Gradual in onset
 - Decline in cognitive ability, judgement, orientation, function at home/work/community

Alzheimer's disease -
The most common cause of dementia in people over age of 65



People with dementia

- A population with complex care needs



**2.5 chronic
conditions
(average)**



**5+
medications
(average)**




**3 times more
likely to be
hospitalized**

**Many admissions
from preventable
conditions,
with higher per
person costs**



- Indisputable correlation between chronic conditions and costs

Neurodegeneration: Diagnosis and Therapeutics Moving Earlier




Neurodegeneration Therapeutics is moving earlier in disease process: the concept of disease interception


From diagnose to biology



The future: going beyond classical diagnostic boundaries for better treatment of psychiatric symptoms in people with dementia?




What does it take to make a drug for Alzheimer's disease?



Nature Reviews | Drug Discovery

The “rights” for a successful treatment for dementia




The "rights" of precision drug development for Alzheimer's disease

[Jeffrey Cummings](#) [✉](#) [Howard H. Feldman](#) & [Philip Scheltens](#)


[Alzheimer's Research & Therapy](#) 11, Article number: 76 (2019) | [Download Citation](#) [↓](#)

For the “rights” to become treatments delivered to the people that need them we need the right strategic approach, programmatic highly collaborative, public-private bringing all stakeholders around the table

Neurodegeneration: a strategic area of IMI2 and a programmatic approach



IMI Projects in neurodegeneration cover the whole value chain



- **End-to-end approach** from discovery through all the way to patient access of innovative medicines;
- Vision of “**personalised**” medicines”: prevention, treatment and health management

Joining the dots: from the Alzheimer's Disease Platform to Neuronet



Facilitate collaboration to help deliver results faster, create efficiencies and create value

A new Health Partnership under Horizon Europe

European Partnership for Health Innovation

[Home](#) [Blog](#) [Consultation](#) [Privacy policy](#)

Why a European Partnership for Health Innovation?

Healthcare in Europe is at a crossroads. It faces increasing challenges on a number of fronts; at the same time, technological and scientific advances offer new opportunities to solve these challenges. Bridging the gap to address today's health and translational challenges will require a multi-sector Public-Private Partnership.

Ensure the voice of people with dementia is heard!



<https://www.euhealthppp.org/consultation>


Visit our new website
www.imi.europa.eu

Sign up our newsletter
bit.ly/IMInewsletter

Follow us on Twitter
[@IMI_JU](https://twitter.com/IMI_JU)

Join our LinkedIn group
bit.ly/LinkedInIMI

Email us
infodesk@imi.europa.eu



Thank you!